Brief report
P300 amplitude and antidepressant response to Sudarshan Kriya Yoga (SKY)

https://doi.org/10.1016/S0165-0327(98)00029-9Get rights and content

Abstract

Background: There is evidence that Sudarshan Kriya Yoga (SKY) has significant antidepressant effects. Objective: The present study examined whether pretreatment P300 ERP amplitude predicts antidepressant response to SKY. Methods: Consenting, drug-free depressed patients (n=30; dysthymics, 15, melancholics, 15) who received SKY as the sole treatment were assessed clinically at pretreatment, 1 month and 3 months. Auditory P300 was recorded before treatment. Results: Twenty-two patients responded favourably to SKY. The pretreatment P300 amplitude neither distinguished responders and non-responders nor was associated with differential rates of response. Discussion: It is concluded that SKY therapy is uniformly effective regardless of the pretreatment P300 amplitude.

Introduction

Sudarshan Kriya Yoga (SKY: Yoga Research Group, 1995) as the sole treatment has been found to be effective in dysthymia in an open trial (Janakiramaiah et al., 1998). Low pretreatment P300 event related potential (ERP) amplitude `normalised' with improvement in both dysthymic (n=15) and melancholic (n=9) patients on SKY therapy (Naga Venkatesha Murthy et al., 1997), similar to earlier reports with somatic treatments such as antidepressant medications and ECT (Blackwood et al., 1987, Gangadhar et al., 1993).

It has been reported, from our laboratory, that depressives with severe `biological' dysfunction, as reflected by low pretreatment P300 ERP amplitude, require longer time for responding and that normal pretreatment P300 ERP amplitude predicts rapid response to a course of ECT (Ancy et al., 1996). Whether this is true with SKY therapy has not been studied. The current study is to examine whether pretreatment P300 ERP amplitude is related to variation in antidepressant response to SKY therapy.

Section snippets

Method

Fifteen patients each of dysthymia (eight males) and melancholia (depressive episode or recurrent depression with somatic syndrome: six males) confirmed by ICD-10 DCR checklist (WHO, 1992) were the sample. Bipolarity, psychotic symptoms, substance use, current drug treatment, major physical illnesses and audiological dysfunction were all excluded. Informed consent for the study was taken. Before SKY treatment auditory odd-ball P300 ERP was recorded with eyes closed, as detailed elsewhere (Naga

Results

The duration and severity of depression (HRSD and BDI scores) differed significantly as expected between the dysthymia and melancholia groups. However, the two groups were comparable on other variables including pretreatment P300 ERP amplitude and latency (Table 1). In the total sample, HRSD total scores did not correlate with the P300 amplitude at pretreatment (Pearson's r=0.07, P>0.7). The two groups were combined for further analysis.

Patients who were rated ≤2 on CGI-Severity, at both 1 and

Discussion

Depression improved significantly following SKY therapy, with significant reductions in both HRSD and BDI scores (Fig. 1). The classification into responder and non-responder groups is validated by the significant differences in these scores at 1 month. Surprisingly, the pretreatment P300 amplitude was comparable between dysthymics and melancholics despite two-fold differences in HRSD scores. Lower P300 ERP amplitude could be a non-specific state marker (Naga Venkatesha Murthy et al., 1997)

Acknowledgements

N.J. is a recipient of a NIMHANS research grant for Yoga in Depression 1994–95 (current study was conducted as a part of this project).

References (10)

There are more references available in the full text version of this article.

Cited by (50)

  • Anti-anxiety efficacy of Sudarshan Kriya Yoga in general anxiety disorder: A multicomponent, yoga based, breath intervention program for patients suffering from generalized anxiety disorder with or without comorbidities

    2015, Journal of Affective Disorders
    Citation Excerpt :

    Our initial hypothesis was that the clinical use of the SKY procedure could reduce anxiety scores, stabilize mental activity, enhance brain function and resilience to stress (Agte, 2008; Meti and Desiraju, 1984; Meti and Raju, 1993). We also considered the antidepressant efficacy of SKY as demonstrated by previous studies (Naga Venkatesh Murthy et al., 1998; Janakiramaiah et al., 1998; 2000; Gangadhar et al., 2000; Rohini et al., 2000; Vedamurthachar et al., 2006). Our findings suggest the following: both patient groups (with and without pharmacological treatment) showed significant improvements in Anxiety and Depression scores after completing the two week intensive segment of the SKY protocol; this improvement was strengthened in the following six months of weekly follow-ups.

  • Effect of Sudarshan Kriya on male prisoners with non psychotic psychiatric disorders: A randomized control trial

    2014, Asian Journal of Psychiatry
    Citation Excerpt :

    Practitioners of SK&P were found to have significantly greater antioxidant production and lower blood lactate levels which might be one of the contributing reasons of greater resilience to daily life stress as noticed in SK&P practitioners (Sharma et al., 2003). SK&P has been most widely studied in depression; upon practicing SK&P, 68% dysthymic patients (Bhatia et al., 2003) and 73% patients suffering from melancholic depression (Naga Venkatesha Murthy et al., 1998) showed remission. SK&P takes three weeks in showing its antidepressant effects (Naga Venkatesha Murthy et al., 1998) and in patients suffering from dysthymia and melancholic depression after 90 days of using SK&P, P300 Evoked response potential (ERP) amplitude readings return to normal (Naga Venkatesha Murthy et al., 1997).

  • Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments

    2009, Journal of Affective Disorders
    Citation Excerpt :

    Long-term data are limited; only one study reported a duration of treatment of longer than 5 weeks. In dysthymia, one RCT (Butler et al., 2008) and four open trials (Janakiramaiah et al., 1998; Lavey et al., 2005; Naga Venkatesha Murthy et al., 1997, 1998) have found yoga useful as monotherapy or augmentation. In summary, there is Level 2 evidence to support the use of yoga, but the quality of trials makes it difficult to interpret these results (Table 2).

View all citing articles on Scopus
View full text